Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.53 |
| ▸ | CNR1 | P21554 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26789822 | 0.86 | ALDH1A1 (0.53) | CNR2CNR1ALDH1A1MAPK14SMN1; SMN2 | |
| SCHEMBL9892786 | 0.86 | ALDH1A1 (0.65) | CNR2CNR1ALDH1A1MAPK14SMN1; SMN2 | |
| SCHEMBL14647382 | 0.85 | ALDH1A1 (0.51) | CNR2CNR1ALDH1A1MAPK14SMN1; SMN2 | |
| SCHEMBL13392769 | 0.85 | CNR2 (0.55) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL9958104 | 0.85 | CNR2 (0.58) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL9892893 | 0.85 | CNR2 (0.55) | CNR2CNR1ALDH1A1MAPK14SMN1; SMN2 | |
| SCHEMBL9891815 | 0.84 | CNR2 (0.54) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL30486167 | 0.84 | CNR2 (0.54) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL9891520 | 0.84 | CNR2 (0.60) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 | |
| SCHEMBL12566298 | 0.82 | CNR2 (0.59) | CNR2CNR1ALDH1A1MAPK14RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885ALDH1A1 1724/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885ALDH1A1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.